Lithium Ion

Lithium Ion

SCHEMBL1110992

COP(=O)(OC)C(NC(=O)OCc1ccccc1)C(=O)[O-].[Li+]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KYNU Q16719 1/20 0.55
ELANE P08246 2/20 0.54
PRTN3 P24158 1/20 0.51
KLK1 P06870 1/20 0.49
ATM Q13315 1/20 0.48
CTRB1 P17538 2/20 0.48
TP53 P04637 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
ALDH1A1 P00352 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29678939 0.91 KYNU (0.62) KYNUELANEPRTN3KLK1ATM
SCHEMBL269404 0.91 KYNU (0.62) KYNUELANEPRTN3KLK1ATM
SCHEMBL187849 0.91 KYNU (0.62) KYNUELANEPRTN3KLK1ATM
SCHEMBL13435790 0.89 KYNU (0.57) KYNUELANEPRTN3KLK1ATM
SCHEMBL535707 0.89 KYNU (0.57) KYNUELANEPRTN3KLK1ATM
SCHEMBL19410220 0.89 KYNU (0.57) KYNUELANEPRTN3KLK1ATM
SCHEMBL13798138 0.88 KYNU (0.56) KYNUELANEPRTN3KLK1ATM
SCHEMBL1110994 0.88 KYNU (0.56) KYNUELANEPRTN3KLK1ATM
SCHEMBL13798136 0.84 KYNU (0.52) KYNUELANEPRTN3KLK1ATM
SCHEMBL12942520 0.82 ELANE (0.61) KYNUELANEPRTN3KLK1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518912-B2 Phosphonic acid derivates and their use as P2Y12 receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2013-08-27 US disclosed
US-8058263-B2 Substituted 2-phenyl-pyridine derivatives ACTELION PHARMACEUTICALS LTD (CH) 2011-11-15 US disclosed
US-20110046089-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES VIATRIS ASIA PACIFIC PTE. LTD. (SG) 2011-02-24 US disclosed
EP-2279191-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2011-02-02 EP disclosed
US-20100261678-A1 PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS VIATRIS ASIA PACIFIC PTE. LTD. (SG) 2010-10-14 US disclosed
EP-2225253-A1 PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2010-09-08 EP disclosed
WO-2009125366-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-10-15 WO disclosed
WO-2009069100-A1 PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046089-A1 SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES P2RY12, P2RY13, P2RY11 KYNU 1350/4885ELANE 2588/4885PRTN3 921/4885
US-20100261678-A1 PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS P2RY12, P2RY13, P2RY11 KYNU 1698/4885ELANE 3447/4885PRTN3 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.